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Abstract
Background
Patient-reported outcome measures (PROMs) can provide valuable information which may
assist with the care of patients with chronic kidney disease (CKD). However, given the large
number of measures available, it is unclear which PROMs are suitable for use in research or
clinical practice. To address this we comprehensively evaluated studies that assessed the
measurement properties of PROMs in adults with CKD.
Methods
Four databases were searched; reference list and citation searching of included studies was
also conducted. The COnsensus-based Standards for the selection of health Measurement
INstruments (COSMIN) checklist was used to appraise the methodological quality of the
included studies and to inform a best evidence synthesis for each PROM.
Results
The search strategy retrieved 3,702 titles/abstracts. After 288 duplicates were removed,
3,414 abstracts were screened and 71 full-text articles were retrieved for further review.
Of these, 24 full-text articles were excluded as they did not meet the eligibility criteria. Fol-
lowing reference list and citation searching, 19 articles were retrieved bringing the total num-
ber of papers included in the final analysis to 66. There was strong evidence supporting
internal consistency and moderate evidence supporting construct validity for the Kidney Dis-
ease Quality of Life-36 (KDQOL-36) in pre-dialysis patients. In the dialysis population, the
KDQOL-Short Form (KDQOL-SF) had strong evidence for internal consistency and struc-
tural validity and moderate evidence for test-retest reliability and construct validity while the
KDQOL-36 had moderate evidence of internal consistency, test-retest reliability and con-
struct validity. The End Stage Renal Disease-Symptom Checklist Transplantation Module
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(ESRD-SCLTM) demonstrated strong evidence for internal consistency and moderate evi-
dence for test-retest reliability, structural and construct validity in renal transplant recipients.
Conclusions
We suggest considering the KDQOL-36 for use in pre-dialysis patients; the KDQOL-SF or
KDQOL-36 for dialysis patients and the ESRD-SCLTM for use in transplant recipients. How-
ever, further research is required to evaluate the measurement error, structural validity,
responsiveness and patient acceptability of PROMs used in CKD.
Introduction
Chronic kidney disease (CKD) is a global health issue [1]. It affects up to 16% of the adult pop-
ulation in the developed world and is associated with increased morbidity and mortality that is
directly related to severity [2, 3]. CKD also has major healthcare economic costs [4, 5]. For the
National Health Service (NHS) in England, the total estimated expenditure attributable to
CKD between 2009 and 2010 was over a billion pounds; renal replacement therapy (RRT)
accounted for approximately half of this expenditure [6]. In the US, it is estimated that manag-
ing stages 3 and 4 CKD cost the Medicare fee-for-service (FFS) approximately $44.4 billion
annually [7].
Early symptoms of CKD, such as fatigue, are usually non-specific [8]. However patients
with more advanced CKD often report multiple ‘clusters’ of symptoms including drowsiness,
pain, pruritus and dry skin [9]. This overall symptom burden may have a negative impact on
the perceived health-related quality of life (HRQOL) of patients with end-stage renal disease
[10, 11].
HRQOL can be assessed using self-administered, validated questionnaires known as
patient-reported outcome measures (PROMs) [12]. PROMs have a wide variety of applications
ranging from clinical trials [13] to product labelling [14] and routine clinical care [15, 16].
There is an increasing awareness that PROMs may have a future role in the management of
patients with kidney disease, including integration into routine practice; for example, through
monitoring patients for symptoms or changes in HRQOL that may require an intervention
[17].
If any benefit is to be derived from the use of PROMs, it is important that they are well vali-
dated to ensure that they actually measure what they are supposed to measure, produce consis-
tent results and capture all aspects of the construct(s) under investigation that matter to the
target population if any benefit is to be derived from their use [14].
A systematic review by Gibbons and Fitzpatrick [18] evaluated the measurement properties
of PROMs used in the CKD population, but this was conducted over six years ago. There have
been methodological advances since then [19, 20] and it is reasonable to assume that new
research has been published [21]. The review was restricted to studies published in English
which might have excluded potentially relevant papers [18]. In addition, the review did not
report evaluating the methodological quality of the selected studies. It is vital that the method-
ological quality of studies evaluating the measurement properties of PROMs is assessed to
ensure that conclusions about the reliability and validity of the measures are dependable [22]
as these have a potential impact on clinical practice and health policy [23].
Therefore, we have evaluated the methodological quality of the selected studies using the
COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN)
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checklist [22] and used the findings to inform our evidence synthesis. Thus providing the best
evidence possible, to inform the selection of PROMs for monitoring the symptoms of CKD
and its treatment effects in pre-dialysis, dialysis and renal transplant patients.
Methods
Design
This systematic review was conducted and reported according to a registered and published
protocol (PROSPERO registration number: CRD42016035554) (See S1 Text. Review Protocol)
[24] and written in compliance with the Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) guidelines (See S2 Text. PRISMA Checklist) [25]. We also consid-
ered the findings of the review of systematic reviews by Terwee et al. [26].
Search strategy
Relevant databases including MEDLINE (Ovid), EMBASE (Ovid), PsycINFO (Ovid) and
CINAHL Plus (EBSCO) were systematically searched from inception to 21st December 2015
without language restrictions [24].
The search strategy was initially developed for MEDLINE and subsequently adapted for the
other databases (See S3 Text. Search Strategy). Two existing search filters [27, 28] were com-
bined with key terms generated by the review team for renal disease and its treatment modali-
ties. An information specialist at the Institute of Applied Health Research, University of
Birmingham, was consulted during the process.
Search records were downloaded into Endnote X7 and duplicates removed. In addition, the
UK Renal Registry website was searched to 17th May 2016.
Screening process
All titles and abstracts were screened independently by two reviewers (OLA and TK/AG).
Full-text articles were obtained for studies potentially meeting the eligibility criteria and were
independently reviewed by the same reviewers. Reasons for exclusion were documented.
Hand searching of reference lists and citation searching of the included papers was also con-
ducted. At all stages, disagreements regarding eligibility were resolved through discussion and,
if necessary, consultation with a third reviewer (MC/DK).
Selection of studies
Studies were included if they: (1) focused on PROMs used specifically for measuring HRQOL
and/or CKD symptoms (the constructs of interest) in any CKD population; and (2) reported
either the development or evaluation of one or more psychometric properties of a PROM [24].
Articles excluded were clinical trial reports, editorials, reviews and conference abstracts. In
addition, studies that focussed on clinician-assessed instruments, PROMs developed for use in
patients with acute kidney injury or in patients below 18 years of age were excluded.
Data extraction
Data from selected studies were extracted independently by two reviewers (OLA and AS)
using a pre-designed data collection form and cross-checked for accuracy.
The following data were extracted where available
1. Characteristics of study populations
2. Questionnaire characteristics
Patient-reported outcome measures (PROMs) used in adult patients with chronic kidney disease
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3. Evidence regarding measurement properties as defined by Mokkink et al.[29] namely: reli-
ability (test-retest reliability, internal consistency, measurement error); validity (content
validity, construct validity (including hypothesis testing, structural validity and cross-cul-
tural validity); responsiveness of questionnaires to changes over time; the setting and
purpose for which the questionnaires were administered and details regarding their
interpretability; operational characteristics including patient acceptability and mode and
feasibility of administration; and details regarding patient involvement in the PROM devel-
opment or validation process.
Appraisal of the methodological quality of selected studies
Following the selection process, the quality of the included papers was assessed by two review-
ers (OLA/AS) using a validated critical appraisal tool for studies of health measurement instru-
ments: the COnsensus-based Standards for the selection of health Measurement INstruments
(COSMIN) checklist [20, 22]. The COSMIN checklist is designed to evaluate the methodologi-
cal quality of studies of psychometric properties [22]. It comprises of mini-checklists A to I
(otherwise known as ‘boxes’) which correspond to each measurement property (See Table 1).
Some measurement properties are named and defined differently by different authors, there-
fore the COSMIN definitions [29] were used to ascertain which measurement properties were
evaluated by the studies. The COSMIN checklist is intended for use as a modular tool meaning
that the mini-checklists (boxes) to be completed for each study will be determined by the mea-
surement properties evaluated by the study [29]. Each mini-checklist has a set of quality items/
questions which were rated individually using the COSMIN 4-point scale as ’excellent’, ’good’,
’fair’ or ’poor’.
An item is rated ‘excellent’ when there is evidence that the methodological quality of
the study in relation to the item is adequate [20]. An item is rated ‘good’ when relevant in-
formation is not reported in an article, but it can be assumed that the methodological quality
is adequate [20]. An item is rated ‘fair’ if there is doubt about the adequacy of the study’s meth-
odological quality in relation to that item [20]. Finally, an item is rated ‘poor’ when there is
evidence that the methodological quality of the study in relation to that particular item is inad-
equate [20]. For example, a small sample size was considered poor methodological quality in
all the mini-checklists. A sample size100 was considered ‘excellent’, 50–99 ‘good’, 30–49
‘fair’, and<30 ‘poor’ [20].
The ’worst score counts’ method was used to determine the methodological quality of each
paper per measurement property [20]. This meant taking as the overall score for each measure-
ment property, the lowest rating given to any item within the respective mini-checklist [20].
Reviewers consulted a third author (MC/DK) if they were unable to reach a consensus at
any point during the assessment.
Data synthesis
The quality criteria developed by Terwee et al. [30] was used to rate the results for each mea-
surement property per study as either ’positive’ (+), ’indeterminate’ (?) or ’negative’ (-). For
example, structural validity was rated as positive, if the factors identified after performing a
factor analysis were reported to explain at least 50% of variance. If the factors explained <50%
of variance structural validity was rated as negative. The indeterminate rating was given if the
percentage of variance explained was not reported. (See Table 1) [30].
An evidence synthesis across studies was then conducted for measurement properties
reported for each PROM using another set of criteria (See Table 2) [19]. At this stage, the
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overall level of evidence for each PROM was provided by one or more studies, taking into
account their methodological quality [20]. The overall level of evidence for each measurement
property was graded as ‘strong’, ‘moderate’, ‘limited’ ‘unknown’ or ‘conflicting’ [19]. For
example, a measurement property was graded as ‘strong’ if at least one study had ‘excellent’
Table 1. Quality criteria for measurement properties.
Property Rating † Quality Criteria
Reliability
Internal consistency + Cronbach’s alpha(s) 0.70
? Cronbach’s alpha not determined or dimensionality unknown
- Cronbach’s alpha(s) < 0.70
Reliability + ICC / weighted Kappa 0.70 OR Pearson’s r 0.80
? Neither ICC / weighted Kappa, nor Pearson’s r determined
- ICC / weighted Kappa < 0.70 OR Pearson’s r < 0.80
Measurement error + MIC > SDC OR MIC outside the LOA
? MIC not defined
- MIC SDC OR MIC equals or inside LOA
Validity
Content validity + All items are considered to be relevant for the construct to be measured, for the target population, and for the purpose of
the measurement AND the questionnaire is considered to be comprehensive
? Not enough information available
- Not all items are considered to be relevant for the construct to be measured, for the target population, and for the purpose
of the measurement OR the questionnaire is considered not to be comprehensive
Structural validity + Factors should explain at least 50% of the variance
? Explained variance not mentioned
- Factors explain < 50% of the variance
Hypothesis testing + Correlations with instruments measuring the same construct 0.50 OR at least 75% of the results are in accordance with
the hypotheses AND correlations with related constructs are higher than with unrelated constructs
? Solely correlations determined with unrelated constructs
- Correlations with instruments measuring the same construct < 0.50 OR < 75% of the results are in accordance with the
hypotheses OR correlations with related constructs are lower than with unrelated constructs
Cross-cultural
validity
+ No differences in factor structure OR no important DIF between language versions
? Multiple group factor analysis not applied AND DIF not assessed
- Differences in factor structure OR important DIF between language versions
Criterion validity + Convincing arguments that gold standard is “gold” AND correlation with gold standard 0.70
? No convincing arguments that gold standard is “gold”
- Correlation with gold standard < 0.70
Responsiveness
Responsiveness + Correlation with changes on instruments measuring the same construct 0.50 OR at least 75% of the results are in
accordance with the hypotheses OR AUC 0.70 AND correlations with changes in related constructs are higher than with
unrelated constructs
? Solely correlations determined with unrelated constructs
- Correlations with changes on instruments measuring the same construct < 0.50 OR < 75% of the results are in
accordance with the hypotheses OR AUC < 0.70 OR correlations with changes in related constructs are lower than with
unrelated constructs
MIC = minimal important change, SDC = smallest detectable change, LoA = limits of agreement
ICC = intraclass correlation coefficient, DIF = differential item functioning, AUC = area under the curve
† + = positive rating,? = indeterminate rating
- = negative rating
(Reproduced with permission from Caroline Terwee, COSMIN)
https://doi.org/10.1371/journal.pone.0179733.t001
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methodological quality or at least two studies had ‘good’ methodological qualities (See
Table 2).
Results
The search strategy retrieved 3,702 titles/abstracts. After 288 duplicates were removed, 3,414
abstracts were screened and 71 full-text articles were retrieved for further review. Of these, 24
full-text articles were excluded for various reasons (Fig 1). Following reference list and citation
searching, 19 articles were retrieved bringing the total number of papers included in the final
analysis to 66. Strength of agreement between the reviewers, calculated using Cohen’s Kappa
Statistic [31], was good (OLA/AG = 0.889, OLA/TK = 0.863).
Description of tables
Table 1 presents the quality criteria used to evaluate the measurement properties for each
PROM while the criteria used for the evidence synthesis are in Table 2. A brief description of
the PROMs evaluated in this review is presented in Table 3. The methodological qualities of
these studies are summarized in Table 4. Table 5 presents the synthesis of the overall level of
evidence for each PROM. The results reported by the included studies were extracted and are
summarized in S1 Table. Summary of study results. The characteristics of the included studies
are presented in S2 Table. Characteristics of included studies. The PROMs evaluated in this
review are summarized in S3 Table. Characteristics of included PROMs. S1–S3 Tables have
been submitted as ‘supporting information’ due to their size.
Evidence synthesis
A total of 25 PROMs were identified from the 66 publications; 20 disease-specific, 3 generic
and 2 utility PROMs (See Table 3). As the included studies were conducted in pre-dialysis,
dialysis and renal transplant populations, the evidence synthesis is described in 3 correspond-
ing sections (See Table 5). The term ‘indeterminate’ was used when vital information required
to assess a measurement property was missing (See Table 1) while ‘unknown’ was used for
measurement properties that were only assessed by studies of poor methodological quality
(See Table 2).
Table 2. Levels of evidence for the quality of the measurement property.[19, 30].
Level of
Evidence
Rating† Criteria
Strong +++ or
—-
Consistent findings in multiple studies of good methodological quality OR in
one study of excellent methodological quality
Moderate ++ or — Consistent findings in multiple studies of fair methodological quality OR in one
study of good methodological quality
Limited + or - One study of fair methodological quality
Conflicting +/- Conflicting findings
unknown ? Only studies of poor methodological quality
† + = positive rating
? = unknown rating
- = negative rating
(Reproduced with permission from Caroline Terwee, COSMIN)
https://doi.org/10.1371/journal.pone.0179733.t002
Patient-reported outcome measures (PROMs) used in adult patients with chronic kidney disease
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Fig 1. Flow diagram.
https://doi.org/10.1371/journal.pone.0179733.g001
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Table 3. Description of PROMs evaluated.
Measure Description
Disease-specific measures: These measure health in a way that is specific to a particular disease, set of
conditions, or part of the body [122].
Agarwal A 37-item HRQOL measure for use in non-dialysis
patients with mental and physical dimensions [32].
Overall scores range from 0 to 100 with higher scores
indicating better HRQOL [32].
Kidney Disease Quality of Life—36 (KDQOL-
36)
A 36-item HRQOL measure designed for use in kidney
disease patients undergoing dialysis. Derived from the
KDQOL-SF [33]. There are 3 specific dimensions namely:
symptoms and problems (ii) burden of kidney disease (iii)
effects of kidney disease. It also includes two summary
scales derived from the SF-12 namely: the physical
(PCS) and mental (MCS) scales [34]. Overall scores
range from 0 to 100 with higher scores indicating better
HRQOL [33].
KDQOL-SF An 80-item HRQOL measure designed for use in kidney
disease patients undergoing dialysis [47]. Derived from
the 134-item KDQOL [47, 58]. Version 1.3 differs from
version 1.2 by the addition of a screening question for
sexual activity [47]. There are 8 generic dimensions from
the SF-36 (See below) and 8 disease-specific dimensions
namely: (i) symptoms/problems (ii) effects of kidney
disease on daily life (iii) burden of kidney disease (iv) work
status (v) cognitive function (vi) quality of social
interaction (vii) sexual function (viii) sleep. There are 3
additional dimensions namely: (i) social support (ii)
dialysis staff encouragement (ii) patient satisfaction.
Scores range from 0 to 100 for each dimension and
higher scores indicate better HRQOL.
Chinese Dialysis Quality of Life Scale (CDQOL) A 29-item measure designed to measure the QOL of
Chinese dialysis patients. Scored on a 5-point Likert
scale. Higher scores indicate better quality of life as
perceived by the patient [49].
CHOICE Health Experience Questionnaire
(CHEQ)
An 83-item HRQOL measure. Designed to complement
the SF-36 and assess the effectiveness of dialysis
modalities [50]. Comprises of 8 dimensions from SF36
(see below) combined with 7 supplementary items and 13
specific dimensions namely: (i) freedom (ii) travel
restrictions (iii) cognitive functioning (iv) financial (v)
restrictions on diet and fluids (vi) recreation (vii) work (viii)
body image (ix) symptoms (x) sleep (xi) sexual
functioning (xii) access-related problems (xiii) quality of
life. An additional 2 person-specific quality of life item.
Possible scores range from 0 to 100 with higher scores
indicating better HRQOL [50].
Dialysis Symptom Index (DSI) A 30-item measure designed to assess symptom
prevalence and severity in patients on haemodialysis [52].
An overall symptom burden score and a total symptom
severity score are calculated. Symptoms are rated on a
5-point Likert scale and total score ranges from 0 to 150
with higher scores indicating greater symptom severity
[52].
Modified Edmonton Symptom Assessment
System (modified ESAS)
This is a measure of symptom burden for use in dialysis
patients. It is a modification of the ESAS. There are 10
symptom-specific items and 10 visual analogue scales
with superimposed 0–10 scale [55]. The scale for each
symptom is anchored by the words ‘No’ and ‘Severe’ at 0
and 10, respectively and the sum of scores range from 0
to 100 with higher scores indicating greater symptom
distress and burden [55].
(Continued )
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Table 3. (Continued)
Measure Description
Kidney Disease Questionnaire (KDQ) A 26-item measure designed to assess the effects of
interventions on the QOL of patients undergoing
haemodialysis [56]. There are 5 dimensions namely: (i)
physical symptoms (ii) fatigue (iii) depression (iv)
relationships with others (v) frustration. Note that the
physical symptom dimension is patient-specific, thus the
symptoms most important to individual patients are
identified and used to evaluate the dimension. Questions
are scored on a 7-point Likert scale and higher scores
indicate a lower impact of disease on HRQOL [56].
KDQOL A 134-item QOL measure designed for use in kidney
disease patients undergoing dialysis [58]. It consists of
SF36 dimensions (see below), 11 kidney disease
targeted scales and an item that assesses change in
health over a year (overall health rating) [58]. All scale
scores are transformed linearly into 0–100 point scales
with higher scores indicating better HRQOL [58].
KDQOL (modified) A 55-item QOL measure derived from the KDQOL [59].
Using affinity mapping, 11 subscales [59] were identified
namely: (i) pain (ii) psychological dependency (iii)
cognitive functioning (iv) social functioning (v) dialysis-
related symptoms (vi) cardiopulmonary symptoms (vii)
sleep (viii) energy (ix) cramps (x) diet (xi) appetite. 4 items
were ungrouped. The measure is scored on a 0 to 100
scale with higher scores indicating better HRQOL [59].
WHOQOL-BREF (Dialysis) A 32-item HRQOL measure modified for use in dialysis
patients with 4 domains (incorporating 4 dialysis-specific
items): (i) physical (ii) psychological (iii) social relationship
(iv) environment. The measure also includes two global
items (general QOL and general health). A 5-point Likert
scale is used and higher scores signify higher HRQOL
[63].
Quality of Life Index (QLI) 3.0 A 68-item QOL measure divided into 2 sections. One
section measures satisfaction with various domains of
life, while the second measures the importance of the
domain to the individual [64]. There are 4 domains: (i)
health and functioning (ii) Social and economic (iii)
psychological/spiritual (iv) family. Each section has 3
additional dialysis-related items. The total QOL score and
the four subscale scores range between 0 and 30 with
higher scores indicating a better HRQOL [64].
End-Stage Renal Disease Symptom Checklist-
Transplantation Module (ESRD-SCL-TM)
A 43-item symptom-specific QOL measure designed for
use in renal transplant patients on immunosuppression
therapy [70]. There are 6 dimensions: (i) limited physical
capacity (ii) limited cognitive capacity (iii) cardiac and
renal dysfunction (iv) side effects of corticosteroids (v)
increased growth of gum and hair (vi) transplantation-
related psychological distress. A 5-point Likert scale is
used. Higher scores indicate worse QOL/symptoms [70].
Modified Transplant Symptom Occurrence and
Symptom Distress Scale (MTSOSD)
A 29-item measure designed to assess side effects of
immunosuppression therapy in renal transplant patients
[74]. The symptom occurrence dimension has 20 items
while the symptom distress dimension has 9 [74]. Ridit
analysis, a statistical method of analysing ordinal data
[123] was chosen for data analysis [74]. Higher ridit
scores indicate greater symptom distress [74].
(Continued )
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Table 3. (Continued)
Measure Description
Gastrointestinal Symptom Rating Scale
(GSRS)
A 15-item measure that assesses important
gastrointestinal side effects of immunosuppressive
therapy in renal transplant patients [75]. There are 5
dimensions: (i) reflux (ii) diarrhoea (iii) constipation (iv)
abdominal pain (v) indigestion. Each dimension gives an
average score ranging from 1 (no discomfort) to 7 (very
severe discomfort) with higher scores indicating worse
impact [75].
Gastrointestinal Quality of Life Index (GIQLI) A 36-item measure which focuses on the impact GI
complaints on the HRQOL of renal transplant patients
[75]. There are 5 dimensions: (i) GI symptoms (ii)
emotional status (iii) physical function (iv) social function
(v) strain of medical treatment. Total scores range from 0
to 144 with higher scores indicating a better HRQOL [75].
Kidney Transplant Questionnaire (KTQ) A 25-item HRQOL measure for use in renal transplant
patients [78]. It has 5 dimensions namely: (i) physical
symptoms (ii) fatigue (iii) uncertainty/fear (iv) appearance
(v) emotional. The physical symptom dimension is
patient-specific, thus the symptoms most important to
individual patients are identified [78]. For each dimension,
an average score ranging from 1 to 7 is calculated with
higher scores indicating better HRQOL in patients [78].
ReTransQoL (RTQ) version 1 A 45-item measure designed to assess QOL in renal
transplant patients [80]. There are 5 dimensions: (i)
physical health (ii) mental health (iii) medical care (iv) fear
of losing graft (v) treatment. All dimensions are linearly
transformed to a 0 to 100 scale and higher scores indicate
better HRQOL [80].
ReTransQoL (RTQ) version 2 A 32-item measure designed to assess QOL in renal
transplant patients [80]. There are 5 dimensions: (i)
physical health (ii) social functioning (iii) medical care (iv)
treatment (v) fear of losing graft. All dimensions are
linearly transformed to a 0 to 100 scale and higher scores
indicate better HRQOL [80].
CKD-Symptom Burden Index (CKD-SBI) A 32-item measure of symptom burden. Derived from the
DSI. The CKD-SBI was developed for use in patients with
CKD stages IV and V however it was used in pre-dialysis
and dialysis populations in this study [82]. The measure
has 4 dimensions namely: (i) prevalence (ii) distress (iii)
severity (iv) frequency. Total score ranges from 0 to 100
and higher scores indicate higher symptom burden [82].
Generic measures: These measure health in a general manner and can be used for various health
conditions [122].
Nottingham Health Profile (NHP) A generic HRQOL questionnaire with 38 yes/no questions
[124] grouped into 6 dimensions: (i) pain (ii) energy (iii)
physical mobility (iv) sleep (v) emotional reactions (vi)
social isolation. There is an optional part. The NHP
scores range between 0 (good health status) and 100
(poor health status) [124].
SF-36 version 2 A generic 36-item HRQOL measure with 8 scales [125]
namely: (i) physical functioning (ii) physical role (iii) bodily
pain (iv) general health (v) vitality (vi) social functioning
(vii) emotional role (viii) mental health. An additional
1-item measure of self-evaluated change in health status
is available. The Likert rating method is used and raw
scores are linearly transformed into 0 to 100 scales with
higher transformed scores indicating better HRQOL
[125].
(Continued )
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Pre-dialysis population. Three disease-specific PROMs were used in pre-dialysis popula-
tions namely the: Agarwal [32], KDQOL-36 [33, 34] and KDQOL-SF [35, 36]. Although the
studies in this section measured estimated glomerular filtration rates (eGFR), there was signifi-
cant disparity in their description of patients at this stage of CKD. Three studies described
patients as ’non-dialysis’ [32], ’mild-to-moderate’ CKD patients [34] and ESRD patients [36]
respectively, while only the studies by Chao et al. [33] and Abd Elhafeez [35] formally catego-
rized patients into CKD stages. None of the studies validated PROMs separately by stage of
CKD pre-dialysis.
Agarwal. There was limited evidence for test-retest reliability and content validity. Internal
consistency and structural validity were rated as ’unknown’ [32].
Kidney Disease Quality of Life—36 (KDQOL-36). Strong evidence for internal consistency
was found [33] and there was moderate evidence for hypothesis testing [33, 34]. Structural
validity was rated as ’indeterminate’ [33].
KDQOL-SF. There was moderate evidence for test-retest reliability [35] and hypothesis
testing [35, 36]. Internal consistency, structural validity and responsiveness were rated as
’unknown’ [35, 36].
Dialysis population. Fourteen PROMS were used in this group of patients. Among the
five studies that evaluated KDQOL-36, two had mixed samples [37, 38]. As the majority of the
participants in Tao et al [38] were on dialysis and no significant transplant specific symptoms
were elicited in Chow et al. [37] a pragmatic decision was made to analyse them here.
Klersy et al. [39] used a sample which comprised of 85% dialysis and 15% pre-dialysis
patients to assess the KDQOL-SF. Again, as the majority were dialysis patients, this study was
analysed in this section.
KDQOL-36. Moderate evidence was found for internal consistency [40], test-retest reliabil-
ity [41, 42] and hypothesis testing [37, 38]. However, structural validity was rated as ’indeter-
minate’ [40].
KDQOL-SF. There was strong evidence of internal consistency and structural validity [43].
Moderate evidence was found for test-retest reliability [44, 45] and hypothesis testing [46]
while there was limited evidence for content validity [47]. Responsiveness was rated as
’unknown’ [48].
Table 3. (Continued)
Measure Description
SF-12 A generic 12-item HRQOL measure derived from the SF-
36 [126] (see above). The 8 dimensions can be computed
into 2 distinct clusters, PCS-12 and MCS-12 with higher
values indicating better HRQOL [126].
Utility measures: These provide utilities or values regarding health and can be used for cost-utility
analyses of interventions [18].
EQ-5D A utility measure with a self-classifier and a visual
analogue scale (VAS) which can be used to value health
states [127]. The self-classifier includes 5 dimensions: (i)
mobility (ii) self-care (iii) usual activities (iv) pain/
discomfort (v) anxiety/depression. Each dimension has 3
levels of severity (no problems, some problems, and
severe problems) and it is possible to describe 243 health
states between 0 (dead) and 1 (perfect health) [127].
Modified Time Trade-Off (TTO) This utility measure was used to measure quality of life in
dialysis and renal transplant populations and values
range from 0 (death) to 1 (full health) [83, 128].
https://doi.org/10.1371/journal.pone.0179733.t003
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Chinese Dialysis Quality of Life Scale (CDQOL). Reliability (internal consistency and test-
retest) for CDQOL was rated as ’unknown’ and there was limited evidence for content validity
and hypothesis testing [49].
Table 5. Evidence synthesis of PROMs used in patients with CKD.
Instrument
version
Population Internal
consistency
Reliability Measurement
error
Content
validity
Structural
validity
Hypothesis
testing
Criterion
validity
Responsiveness
Agarwal [32] Pre-
dialysis
? + + ? -
KDQOL-36 [33, 34,
37, 38, 40–42]
Pre-
dialysis
+++ ?* ++
Dialysis ++ ++ ?* ++
KDQOL-SF [35, 36,
39, 43–48, 76, 85–
96, 102]
Pre-
dialysis
? ++ ? ++ ?
Dialysis +++ ++ + +++ ++ ?
Transplant ? - +
CDQOL [49] Dialysis ? ? + +
CHEQ [50, 51] Dialysis ? ++ ++
DSI [52, 53] Dialysis ? ? +
ESAS [54, 55] Dialysis + + + ?
KDQ [56, 57] Dialysis ? + + ? ++ ?
KDQOL (D)[58] Dialysis ? + ?
KDQOL (M)[59] Dialysis ? +
NHP [60, 61] Dialysis ++ ? +
SF-12 [62] Dialysis ++ ++ + +
WHOQOL-BREF
(D) [63]
Dialysis ++ ? ? -
QLI 3.0 [64–67] Dialysis ? - ? ++
SF-36 v2 Dialysis
[68]
++ +
Transplant
[69]
? -
ESRD-SCL [70–72] Transplant +++ ++ + ++ ++ ?
EQ-5D [73] Transplant ++
GIQLI [75] Transplant ? ++
GSRS [75] Transplant ? ++
KTQ [77–79, 84] Transplant ++ + + ? ++ ?
MTSOSD [74] Transplant ++
RTQ v1 [80, 81] Transplant ? ? ++ +/- + ?
RTQ v2 [81] Transplant ++ ++ +
TTO (modified)
[83]
Mixed (D &
TX)
+ +
CKD-SBI [82] Mixed (D &
Pre-D)
? +
+ = positive rating
? = unknown rating
- = negative rating
+/- = conflicting findings
?* = indeterminate rating (due to non-reporting of variance explained by factors)
https://doi.org/10.1371/journal.pone.0179733.t005
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CHOICE Health Experience Questionnaire (CHEQ). Moderate evidence for hypothesis testing
and content validity was found [50] while internal consistency was rated as ’unknown’ [50, 51].
Dialysis Symptom Index (DSI). There was limited evidence for content validity [52]. Reli-
ability (internal consistency and test-retest) was rated as ’unknown’ [52, 53].
Modified Edmonton Symptom Assessment System (modified ESAS). There was limited
evidence of test-retest reliability, content validity and hypothesis testing. Responsiveness was
rated as ’unknown’ [54, 55].
Kidney Disease Questionnaire (KDQ). There was moderate evidence of hypothesis testing
[56, 57] while there was limited evidence for test-retest reliability and content validity [56].
Structural validity, responsiveness [56] and internal consistency [57] were rated as ’unknown’.
KDQOL. There was limited evidence for content validity while internal consistency and
structural validity were rated as ’unknown’ [58].
KDQOL (Modified). There was limited evidence for hypothesis testing while internal con-
sistency was rated as ’unknown’ [59].
Nottingham Health Profile (NHP). There was moderate evidence for internal consistency
[60, 61] and limited evidence for hypothesis testing [60]. Test-retest reliability was rated as
’unknown’ [61].
SF-12. Moderate evidence was found for internal consistency and test-retest reliability.
There was limited evidence for structural validity and hypothesis testing [62].
WHOQOL-BREF (Dialysis). There was moderate evidence for internal consistency while
test-retest reliability and structural validity were rated as ’unknown’ [63].
Quality of Life Index (QLI) 3.0. There was moderate evidence for hypothesis testing [64,
65]. Internal consistency and structural validity were rated as ’unknown’ [64–67] while there
was limited evidence against test-retest reliability [67].
SF-36 version 2. Moderate evidence was found for internal consistency while limited evi-
dence was found for hypothesis testing [68].
Renal transplant population. Ten PROMs were evaluated specifically in renal transplant
patients and all except the SF-36 and the EQ-5D were disease specific measures.
SF-36 version 2. Internal consistency was rated as ’unknown’ [69].
End-Stage Renal Disease Symptom Checklist–Transplantation Module (ESRD-SCL-TM).
There was strong evidence for internal consistency [70, 71], moderate evidence for test-retest
reliability [71, 72], hypothesis testing [72] and structural validity [71]. There was limited evi-
dence for content validity [70] while responsiveness was rated as ’unknown’ [71].
EQ-5D. Moderate evidence for hypothesis testing was found [73].
Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD). Mod-
erate evidence for hypothesis testing was found for MTSOSD [74].
Gastrointestinal Symptom Rating Scale (GSRS). Moderate evidence for hypothesis testing
was found while internal consistency was rated as ’unknown’ [75].
Gastrointestinal Quality of Life Index (GIQLI). Moderate evidence for hypothesis testing
was found while internal consistency was rated as ’unknown’ [75].
KDQOL-SF. There was limited evidence for hypothesis testing and limited evidence against
test-retest reliability. Internal consistency was rated as ’unknown’ [76].
Kidney Transplant Questionnaire (KTQ). There was moderate evidence for internal consis-
tency [77] and hypothesis testing [78, 79]. Limited evidence was found for test-retest reliability
[77] and content validity [78] Structural validity [77] and responsiveness [79] were rated as
’unknown’.
ReTransQoL (RTQ) version 1. There was moderate evidence of content validity [80], con-
flicting evidence of structural validity [80, 81] and limited evidence of hypothesis testing [80].
Internal consistency, test-retest reliability and responsiveness were rated as ’unknown’ [80].
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RTQ version 2. This revised version had moderate evidence for internal consistency and
structural validity. There was still limited evidence for hypothesis testing [81].
Single studies with mixed samples. The study by Almutary et al. [82] evaluated the
CKD-Symptom Burden Index (CKD-SBI) in a mixed sample of pre-dialysis and dialysis
patients while Churchill et al. [83] assessed the Time Trade-Off (TTO) in a mixed sample of
dialysis and renal transplant recipients.
CKD-Symptom Burden Index (CKD-SBI)
Limited evidence was found for hypothesis testing while internal consistency was rated as
’unknown’ [82].
Modified Time Trade-Off (TTO)
There was limited evidence for test-retest reliability and hypothesis testing [83].
Other findings
Reliability. Internal consistency: Of the 58 studies that assessed internal consistency, 42
were scored ’poor’ for methodological quality. This was due to one of 3 reasons:
1. Some studies did not conduct a factor analysis and did not reference a relevant study that
conducted one [41, 49–51, 53, 61, 64, 75, 82].
2. Some studies conducted a factor analysis but had inadequate sample sizes by COSMIN
standards [32, 35, 39, 47, 59, 65, 78, 80].
3. Some studies referenced a relevant study that conducted a factor analysis but the sample
size used for the study was inadequate by COSMIN standards [34, 36, 37, 44–48, 57, 66, 67,
69, 76, 79, 84–95].
Test-retest reliability: Thirty-four studies conducted test-retest reliability and most of them
reported internal correlation coefficients (ICC). The study by Duarte et al. [96] was the only
one that reported inter & intra-observer reliability. The majority scored ’fair’ for test-retest
reliability and this was largely due to the small sample sizes.
Measurement error: The included studies did not provide adequate information on param-
eters such as the minimal important change (MIC) [97], the standard error of measurement
(SEM) [30, 98] or the limits of agreement (LOA) [99] making it difficult to assess measurement
error. Only one study provided an estimate for minimal clinical important difference (MCID)
[75].
Validity. Content validity: This was assessed by development studies for RTQ [80], modi-
fied ESAS [55], Agarwal [32], CHEQ [50], CDQOL [49], DSI [52], KDQ [56], KTQ [78],
KDQOL [58], KDQOL-SF [47]. Six validation studies reported content validity indexes (CVI)
[33, 38, 49, 53, 77, 82] and of these only Suet-Ching [49] reported patient involvement in the
process of content validation.
Construct validity (Hypothesis testing): Of the 66 studies evaluated, only 13 reported clearly
formulated a priori hypotheses or expectations regarding the magnitude and direction of cor-
relations. For this reason, most of the studies were rated as ’fair’ for the methodological quality
of their hypothesis testing.
The absence of clear a priori hypotheses make it difficult to determine whether any results
reported for construct validity and responsiveness was due to chance or not [100, 101].
Structural validity: A number of measures were rated poorly for structural validity due to
issues with factor analysis (See internal consistency). Out of the 19 studies that conducted a
factor analysis, 8 were scored ’poor’ [32, 35, 39, 56, 58, 65, 78, 80] and this can be attributed to
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the use of sample sizes inadequate by COSMIN standards (n< 5 times the total number of
items and< 100) [100]. It is important that studies perform factor analysis as it verifies scale
structure and uni-dimensionality which determines the scoring and interpretation of a mea-
sure’s internal consistency statistic [100].
Criterion validity: This was not assessed for any study as the COSMIN Delphi panel does
not regard any PROM as true ’gold standard’ [29] and the FDA holds a similar view [14].
Cross-cultural validity/Translations: Twenty-five studies translated PROM instruments and
adapted them to varying degrees for their study population. As none of these studies per-
formed a multi-group confirmatory factor analysis or assessed differential item functioning
(DIF) between language groups, the decision was made not to assess cross-cultural validity.
Therefore, only the quality of their translations was assessed according to the provisions speci-
fied in the COSMIN manual [100].
The translations conducted by 20 studies [33, 35, 39, 42, 44–46, 48, 51, 53, 57, 65, 72, 77, 85,
88, 92, 94, 96, 102] were rated as good, while the translations by 4 studies [66, 67, 82, 91] were
rated as fair and 1 translation was rated as poor [79].
Responsiveness. Responsiveness was only assessed by 8 of the included studies [36, 48, 54,
56, 71, 78–80] and all were rated ‘poor’ as the information provided was inadequate.
Interpretability. A number of the PROMs included in this review had significant floor
and ceiling effects which might indicate a reduction in their ability to discriminate between
patients with the lowest or highest possible scores and detect changes over time [30].
Ten instruments (KDQOL-SF, Agarwal, KDQ, KDQOL-36, KTQ, QLI, KDQOL,
ESRD-SCL, CHEQ and NHP) had floor and ceiling effects > 15% while the RTQ v2 and SF-12
[62, 81] had< 15%.
The ‘work status’ dimension of the KDQOL-SF had a 70% floor effect [45, 86] while the
‘social support’, ‘patient satisfaction’ and ‘staff encouragement’ domains had ceiling effects of
46%, 45% and 67% [86], respectively. Sexual function had ceiling effects of 53.3% while cogni-
tive function had ceiling effects of 60% [35]. The ‘pain’ dimension of the SF-36 had ceiling
effects as high as 59% [35].
Eight studies namely; RTQ v1 [80], RTQv2 [81], GSRS & GIQLI [75], KDQOL-36 [38, 41],
KDQOL-SF [44], CHEQ [51], TTO [83] reported measurement scores for subgroups within
their study populations. While some of the differences in scores were statistically significant, it
is unclear if any were clinically relevant.
Feasibility and acceptability. This was difficult to assess for the included studies as less
than a third reported the average time needed to complete the questionnaires, few reported the
recall period used and none reported administrative requirements for collection and analysis
of data. However, most of the studies reported good response rates which suggest that patients
might find the use of PROMs acceptable.
The fact that majority of the studies failed to report the level and/or the method used for
handling missing data meant there might be a risk of bias [101]. Questions relating to sexual
activities had the highest levels of missing data with Bataclan and Dial [88] reporting a
response rate of<18% in Filipino patients [88].
Patient involvement. Patient involvement in the process of item generation and/or item
selection was reported in the development of the RTQ [80], KDQ [56], KTQ [78],
ESRD-SCLTM [70], KDQOL-SF [47], Agarwal [32], CHEQ [50], QLI 3.0 [64], KDQOL (Dial-
ysis) [58] and CDQOL [49].
All the studies that translated and adapted measures reported pre-testing their translations
in patients to assess a combination of comprehension, cultural relevance and acceptability
except Rebollo et al.[79]
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Discussion
This is the first review to use the COSMIN checklist [100] to evaluate the measurement prop-
erties of PROMs used in patients with CKD. In all, 25 PROMs were evaluated by a total of 66
studies in pre-dialysis, dialysis, and renal transplant patients.
In the pre-dialysis population, the KDQOL-36 exhibited strong evidence for internal con-
sistency and moderate evidence for construct validity (hypothesis testing). It should be noted
that the evidence for this measure was obtained from studies conducted in Taiwanese patients
[33], and a combination of Hispanic and non-Hispanic white patients [34]. Furthermore, the
measurement properties were not reported by CKD stage. Therefore, further validation may
be necessary before use outside these study populations and/or where focus is on the use of
PROMs in relationship to the severity of CKD.
In dialysis patients, we found evidence to support the use of both the KDQOL-SF and the
KDQOL-36. The KDQOL-SF demonstrated strong evidence for internal consistency and struc-
tural validity and moderate evidence for test-retest reliability and construct validity (hypothesis
testing) while the KDQOL-36 had moderate evidence for internal consistency, test-retest reliabil-
ity and construct validity (hypothesis testing). Again it should be noted that this evidence was
obtained from a significant number of non-English studies, further validation work would be
needed before these measures could be confidently utilised in an English speaking population.
In renal transplant patients, the ESRD-SCLTM demonstrated strong evidence for internal
consistency and moderate evidence for test-retest reliability, structural validity and construct
validity (hypothesis testing).
Consistent with the review by Gibbons and Fitzpatrick [18], much of the evidence we pres-
ent was derived from cross-sectional studies. However, in contrast to that study, we did not
include clinical trial reports as the methodological quality of their PROM evaluations are often
unsatisfactory [23] and their PROM analysis often inadequate and insufficiently [103] reported
for any meaningful evaluation to be possible [19].
In line with our findings, Gibbons and Fitzpatrick [18] found evidence to support the use of
the KDQOL-SF but did not specify which modality of renal replacement therapy (RRT) pro-
vided the evidence. We found evidence to support the use of the KDQOL-36 (which was not
available at the time Gibbons and Fitzpatrick [18] conducted their review), and the
ESRD-SCLTM (which was excluded from their study) [18]. The ERA-EDTA expert panel
[104] recommended the KDQOL-36, following a consensus meeting.
There were methodological issues with the majority of the PROMs included in this review.
These included: sample sizes smaller than current recommendations, a lack of clearly
described a priori hypotheses and inadequate reporting of missing data, and little or no infor-
mation on measurement error and responsiveness. Similar issues were reported by Gibbons
and Fitzpatrick [18] and highlighted in reviews for other health conditions [105–107].
Given that the COSMIN standards only became available within the last decade, it is unsur-
prising that most of the earlier studies fared poorly when judged against these exacting meth-
odological and reporting standards even though they might meet the minimum standards
recommended by the International Society for Quality of Life Research (ISOQOL) [108].
However, this highlights the need to test and revise PROM instruments on a regular basis to
ensure they actually perform as intended according to contemporary psychometric standards.
This systematic review provides a basis for identifying PROMs with potential utility in clini-
cal practice. There is evidence that the use of PROMs in clinical practice could enhance com-
munication [109–112] between patients and their clinicians. Basch et al. [113] noted that the
use of PROMs in routine clinical care, could facilitate the reporting of serious adverse events
due to drug toxicities [113], while a review by Finkelstein et al. [114] suggested that the use of
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PROMs could assist renal teams with the development of strategies to improve the HRQOL of
the patient with CKD [114]. Calvert et al. [115] suggested that PROM data could potentially
facilitate the delivery of tailored healthcare if successfully integrated with routinely collected
clinical and laboratory data [115].
Whilst effective management of risk factors can slow CKD progression [116] many patients
with severe pre-dialysis CKD progress to end stage renal disease (ESRD) and in this group
PROMs may have a significant role [117–119]. For example, PROMs could be used to monitor
individual patients for symptoms or changes in HRQOL that may indicate that a medical
review or intervention is needed [17, 120].
Whilst a systematic review can provide valuable evidence on psychometric properties of
PROMs, clinicians and researchers need to consider a number of issues such as the domains
covered by different measures, the available supporting evidence, and the suitability for the tar-
get population and use (whether for clinical trials, routine practice, audit or real-time decision
making). As no single measure covers all the domains that might be of interest, there might be
a need to administer more than one measure. Patient acceptability is also a key issue. There-
fore, it is important that patients are involved not just in the development of measures but also
in the selection for research and/or practice.
During the course of this review, we became aware of the existence of the IPOS-Renal and
contacted its developers [121]. This measure is currently being used within the measurement
work stream of the UK Renal Registry and its validation by the Palliative care Outcome Scale
(POS) team is on-going [121]. Therefore, evidence to support its use may be available in future.
The key strengths of this review are the use of the COSMIN standards and criteria for evi-
dence synthesis which ensured that our assessments of the included PROMs were robust, the
stratification of the review by stage of CKD and the absence of language restrictions which
strengthened our findings. The main limitation is the fact that the included studies did not
adequately report their assessments for a number of measurement properties thus making it
difficult and sometimes impossible to evaluate these properties.
At present, we suggest the use of the KDQOL-36 in pre-dialysis patients though initial vali-
dation might be required. We recommend the KDQOL-SF and the KDQOL-36 for use in dial-
ysis patients as we found evidence supporting both of these measures. The shorter 36-item
KDQOL-36 may be more practical for use in routine clinic settings, while the longer 80-item
KDQOL-SF might be preferred for research purposes where more detailed information may
be required. We suggest using the ESRD-SCLTM in renal transplant recipients to assess issues
pertaining to renal transplantation and immunosuppression therapy. These measures are rec-
ommended based on the fact that they currently possess the best evidence available according
to COSMIN standards in these populations and meet the minimum standards recommended
by ISOQOL [108]. However, it must be recognised that none of these measures possess evi-
dence underpinning all measurement properties and some lack validation in English-speaking
populations. Future work should be undertaken to address these gaps. For all measures, it is
vital that content validity is established according to FDA guidelines to ensure that they actu-
ally measure the concept(s) of interest. This should be conducted before other measurement
properties are fully evaluated and adequately reported in order to facilitate their subsequent
evaluation. Investigators may use this review to identify the gaps in evidence and design stud-
ies to address these issues in future.
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